Signs of the disease are generally not noticeable before the age of 15. It can occur in children as young as 3 years old and in adults. Signs usually last for 2 weeks or more and include fever, weight loss, vomiting, and fatigue. On blood tests the white blood cell count and red blood cell counts are generally increased.
Today, the cure rate for B-cell is 15%. The treatments most likely to cure B-cell leukemia are chemotherapy and allogeneic stem cells. A cure rate for leukemia the other way around has not been achievable yet. Therefore, even though patients with B-cell cancer have a good chance of being cured, the chances to find a cure for those with leukemia is not high. Researchers are continuously working to improve outcomes and to find a cure for leukemia. If you have a disease that is similar to B-cell leukemia and you want to search for treatment trials that are specifically designed for the disease at hand, you have to use the [Power](http://www.withpower.
In the United States, there are approximately 50,000 cases of ALL and 40,000 cases of CLL/Hodgkin a year. AML is relatively uncommon, with an incidence of about 700 cases a year.
Leukemia, lymphocytic, chronic, b-cell is a type of blood or bone marrow cancer that forms within the lymphatic cells of the bone marrow and blood and destroys or changes blood and marrow cells. In the UK it comprised 23% of all lymphocytic and [chronic lymphocytic leukemia](https://www.withpower.com/clinical-trials/chronic-lymphocytic-leukemia)s reported to the Cancer Registry of the United Kingdom in 2005. It occurs throughout all ages, accounting for about 4% of all cases of acute leukemias of childhood and adolescents. The lifetime risk of developing leukemias is around 5 per 10,000, although more than half of individuals who developed leukemias died within five years of diagnosis.
Treatment of multiple types of leukemia are common. Frequently used treatments include induction chemotherapy, anthracyclines, steroids, antihistamines, and antifungals. The use of drugs that suppress the immune response to leukemic cells is less often used. The use of chemotherapy to treat ALL and the other subtypes of ALL are now the preferred treatment modalities. In most cases, the treatment is directed against the leukemic cells, but targeted agents against lymphoproliferative and autoimmune disease are becoming more common. Finally, newer agents such as imatinib and nilotinib are available and are increasingly used. The use of allogeneic bone marrow transplantation has become more common over the last decade.
Acute lymphocytic leukemia is caused by an unusually high number of mutated cells. Lymphocytic lymphoproliferative disorders and myeloproliferative neoplasms arise because B-cells proliferate abnormally. The leukemia-like effects of chronic lymphocytic leukemia stem from the dysregulation of key B-cells, and the myeloproliferative effects of acute myelogenous and chronic myelogenous leukemia involve a clone of mutated cells. Leukemia can have a long latency period, allowing for the accumulation of multiple genetically abnormal cells over a long period of time.
The likelihood of developing the type of leukemia, lymphocytic, chronic, b-cell increases if you are a male and/or if your parents have a history of the disease or if you have a current immune system condition. The probability increases if you are older than the age of sixty. The likelihood of developing this type of cancer is greater if you are a black person or have a history of a cancer of African heritage. The chances of developing cancer of this type increase as you get older.
This treatment regimen was as effective as a cyclophosphamide regimen in patients with relapsed chronic lymphocytic/small cell leukemia of prolonged duration. The cyclophosphamide was also associated with fewer side effects or other adverse occurrences, particularly in patients treated for a greater number of cycles.
[The average age a patient of leukemia is 55 years, lymphocytic is 41 years, chronic is 36 years; median age a patient is 45 years.] (https://en.wikipedia.org/wiki/Lymphocytic_leukemia/Lymphocytic_chronic-cell_leukemia) (http://en.wikipedia.org/wiki/List_of_malignancies_associated_with_leukemia#Lymphocytic_leukemia_chronic_cell_leukemia). The incidence of leukemia is increasing steadily for people of all ages in the United States. [It is increasing at a rate of 1% per year.] (http://www.cdc.
In a recent study, findings showed that the disease had a slow spread in the lymph nodes. We observed a spread very slowly in the liver, spleen and bone marrow, and in the brain, we observed fast spread. In the patients, it was possible to observe a decline in white blood cells and a rapid decrease in lymphocytes. The disease of [chronic lymphocytic leukemia](https://www.withpower.com/clinical-trials/chronic-lymphocytic-leukemia) and leukemia, chronic, b-cell with a decrease in blood cells was associated with an increased risk of secondary disease.
Cyclophosphamide was a major drug used for treating lymphoproliferative diseases. Cyclophosphamide was widely used off label to treat and prevent relapse from hematological malignancies. Unfortunately, it also caused severe side effects. Although the exact mechanism of action of cyclophosphamide is unknown, it was shown to selectively kill lymphocytes and monocytes in vivo and in vitro. Due to its toxicities, cyclophosphamide is no longer used as an effective treatment for acute leukemia. Recent studies, however, show that there are some indications that cyclophosphamide may be clinically effective for treating chronic lymphocytic leukemia or chronic myelogenous leukemia.
There is substantial variation across physicians' opinions of how cyclophosphamide is prescribed. Further research is needed to determine the best way to support the clinical use of cyclophosphamide, particularly with regard to the most effective treatment dosage.